Sign In
Buy GLP
$48.45
-0.81 (-1.64%)
At Close: Jun 03, 2026
Forget Ozempic: This High‑Flying Device Maker Can Thrive No Matter Which Weight Loss Drug Wins
01:15pm, Friday, 20'th Feb 2026
Novo Nordisk's GLP-1 pill has reignited the competition in the GLP-1 space. But you can sidestep that drama by buying this surgical robotics pioneer.
Novo Nordisk's Wegovy® Pill Achieves Strong First-Month Uptake, Signaling Expanding Demand for Oral GLP-1s in Obesity
07:58am, Friday, 20'th Feb 2026
Awareness and prescribing of the Wegovy pill for weight loss surge among primary care physicians and endocrinologists following its January launch. Awareness and prescribing of the Wegovy pill for wei
Healthy Returns: FDA chief Marty Makary on compounded GLP-1s, vaccines and China
02:52pm, Thursday, 19'th Feb 2026
Makary helms the FDA in the midst of a contentious stretch for the agency, defined by massive staff and budget cuts and sweeping changes to vaccine policy.
Moonage Media Review: Clearmind's MEAI and GLP-1 - Are These the Next-Generation Treatment for Weight Loss?
01:05pm, Thursday, 19'th Feb 2026
HONG KONG, Feb. 19, 2026 /PRNewswire/ -- As the multi-billion-dollar obesity treatment market continues to search for new therapeutic approaches beyond GLP-1–based treatments, Clearmind Medicine (Na
Hims & Hers GLP-1 pill gambit backfires, accelerating crackdown on drug compounders
06:04am, Thursday, 19'th Feb 2026
Online telehealth company Hims & Hers Health , seeking growth drivers as its original sexual-health franchises matured, may have overstepped with a risky launch of weight-loss pills that drew swift bl
Flowers Foods: Dividend Cut Fears And GLP-1 Panic Are An Opportunity
04:21am, Wednesday, 18'th Feb 2026
Flowers Foods remains a Strong Buy, with deep value and recovery potential despite near-term consumer headwinds and soft 2026 guidance. FLO's robust free cash flow and solid balance sheet underpin int
CollPlant Targets New Aesthetic Market Driven by GLP-1 Weight-Loss Treatments
07:00am, Tuesday, 17'th Feb 2026
Next-generation rhCollagen-based technology aims to restore facial structure and skin quality in patients experiencing volume depletion linked to GLP-1 weight-loss therapies REHOVOT, Israel, Feb. 17,
Global Partners LP to Host Fourth-Quarter and Full-Year 2025 Financial Results Conference Call on February 27, 2026
08:30am, Thursday, 12'th Feb 2026
WALTHAM, Mass.--(BUSINESS WIRE)--Global Partners LP (NYSE: GLP) (“Global Partners” or the “Partnership”) today announced that it will release its fourth-quarter and full-year 2025 financial re
More than a third of patients on Wegovy pill are new to GLP-1 drugs, study finds
01:12pm, Wednesday, 11'th Feb 2026
Among early users of Novo Nordisk's new Wegovy weight-loss pill, 36% had no prior experience taking a GLP-1 medication, a new study from the health data firm Truveta found.
Expands Wellness Platform with Targeted GLP-1 Support Products Focused on Fiber, Vitality, and Protein Kick. Sports Nutrition® Expands with New Flavor Innovations Across Protein and Pre- and Post-Wor
Viking Therapeutics: The Under‑the‑Radar GLP‑1 Contender Growth Hunters Can't Ignore
01:15am, Wednesday, 11'th Feb 2026
Viking Therapeutics is advancing weight loss candidates through phase 2 and phase 3 trials. Results so far have been very promising.
Why Cheaper GLP-1 Drugs Are Facing Legal Battles
01:01pm, Tuesday, 10'th Feb 2026
The push to make weight loss drugs more affordable is running into legal limits. Telehealth company Hims & Hers pulled a less expensive oral version of Wegovy after lawsuits from Novo Nordisk and risi
Thinking About Investing in GLP-1 Stocks? Here Are 3 Things You Need to Know
01:00pm, Tuesday, 10'th Feb 2026
The growth potential in the GLP-1 market could help healthcare stocks soar in value. Competition, however, is likely to be fierce.
Hims & Hers Health: The GLP-1 Trade Just Got Real (Rating Downgrade)
09:53am, Tuesday, 10'th Feb 2026
Downgrading Hims & Hers Health, Inc. to Hold as the GLP-1 downside catalysts feel very real now. The FDA signaled new limits on non-approved compounded GLP-1 APIs being mass-marketed, and it explicitl
Eli Lilly Is Partnering with Gene-Editing Start-up Seamless Therapeutics. Here's What Investors Need to Know.
09:15am, Tuesday, 10'th Feb 2026
Eli Lilly's GLP-1 drugs have seen strong demand, which has investors excited about the future. The company knows that its GLP-1 success won't last forever and is exploring additional paths.
